HC Wainwright Brokers Boost Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – HC Wainwright increased their Q4 2026 EPS estimates for shares of Corcept Therapeutics in a report released on Thursday, January 22nd. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.81 for the quarter, up from their previous forecast of $0.74. HC Wainwright has a “Buy” rating and a $105.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share.

CORT has been the topic of a number of other research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. UBS Group assumed coverage on Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target for the company. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Truist Financial set a $50.00 price objective on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. Finally, Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research note on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $83.50.

Corcept Therapeutics Stock Up 6.5%

NASDAQ CORT opened at $43.98 on Monday. The firm has a market cap of $4.63 billion, a PE ratio of 49.98 and a beta of 0.23. Corcept Therapeutics has a one year low of $32.99 and a one year high of $117.33. The stock’s 50 day simple moving average is $65.24 and its 200 day simple moving average is $71.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The firm had revenue of $207.64 million for the quarter, compared to the consensus estimate of $223.78 million. During the same period in the prior year, the company posted $0.41 earnings per share. Corcept Therapeutics’s quarterly revenue was up 13.8% compared to the same quarter last year.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.52, for a total value of $1,590,400.00. Following the transaction, the insider directly owned 7,904 shares of the company’s stock, valued at approximately $628,526.08. This trade represents a 71.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $73.65, for a total transaction of $368,250.00. Following the sale, the insider owned 10,277 shares of the company’s stock, valued at $756,901.05. The trade was a 32.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 194,500 shares of company stock valued at $14,186,410. 20.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Large investors have recently bought and sold shares of the company. Royal Bank of Canada raised its stake in shares of Corcept Therapeutics by 18.9% in the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after purchasing an additional 2,444 shares during the period. Amundi acquired a new position in Corcept Therapeutics during the first quarter worth $450,000. NewEdge Advisors LLC acquired a new stake in Corcept Therapeutics in the 1st quarter valued at $518,000. Wealth Enhancement Advisory Services LLC lifted its position in Corcept Therapeutics by 71.6% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 13,647 shares of the biotechnology company’s stock worth $986,000 after buying an additional 5,693 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of Corcept Therapeutics by 277.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 910 shares of the biotechnology company’s stock worth $67,000 after buying an additional 669 shares during the last quarter. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 3 ROSELLA met its overall survival primary endpoint in platinum‑resistant ovarian cancer — a clear clinical success that materially improves relacorilant’s value thesis and is the main driver of the move. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
• Positive Sentiment: Multiple trade and analyst outlets reported the OS win, reinforcing market confidence that the drug could drive future revenue and partnership interest. CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
• Positive Sentiment: Wall‑street coverage (e.g., Reuters) flagged the late‑stage success, increasing visibility with institutional investors and media, which can amplify buying interest. Corcept’s cancer drug meets main goal in late-stage trial
• Positive Sentiment: Analyst optimism picked up: Canaccord raised its price target to $100 and maintained a buy rating, signaling upside potential versus the current price and likely supporting additional demand. CORT Corcept Therapeutics price target raised by Canaccord
• Neutral Sentiment: Options flow shows elevated activity: about 4,870 put contracts were purchased (≈78% above the typical daily put volume), indicating some investors are hedging or speculating on near‑term volatility rather than a clear directional consensus. (No external link)
• Negative Sentiment: Regulatory and legal overhangs remain — shareholder law firms (Hagens Berman and Pomerantz) launched investigations tied to the company’s prior FDA complete response letter for relacorilant in Cushing’s syndrome and the sharp December sell‑off, which could lead to litigation costs or disclosure risk. CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
• Negative Sentiment: Remember the December FDA complete response letter for relacorilant (Cushing’s syndrome) that previously drove a large share price drop — regulatory uncertainty remains a material risk even after the oncology win. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated – CORT

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.